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Introduction
Canavan disease (CD) is a type of vacuolating leukodystrophy with autosomal 
recessive inheritance (1). This neurodegenerative disorder is caused by a defect in 
the aspartoacylase (ASPA) gene encoding the critical enzyme aspartoacylase, which 
has the role of hydrolyzing N-acetyl-L-aspartic acid (NAA) and providing the acetyl 
group to oligodendrocytes for myelin synthesis (2, 3). Aspartoacylase deficiency 
results in the reduction of myelin biosynthesis, dysmyelination and brain edema (4).
Although CD is very common in Ashkenazi Jews, several cases have also been 
reported from non-Jewish population (4). To date mutation analysis on ASPA gene 
among Jewish and non-Jewish patients has revealed more than 70 different types 
of mutations (2). E285A (p.Glu285Ala) and Y231X (p.Tyr231X) mutations are the 
most common types of mutations identified among Ashkenazi Jews (more than 98% 
of reported mutations) while A305E (p.Ala305Glu) is the most common among 
non-Ashkenazi Jewish population (about 30-60% of reported mutations) (5, 6).
This report is based on a homozygous C.202G>A mutation in the ASPA gene of 




This report is on a 10 months old male infant who was born through normal vaginal 
delivery with birth weight of 2900 grams (gm), head circumference of 33 centimeters 
(cm) and height of 49.5 cm. He was the first child of consanguineous parents (first 
cousin) and his mother had no previous history of abortion or dead fetus. The child 
was nearly normal until the age of 3 months when he gradually developed lethargy, 
poor feeding, and inability to hold his neck with progressive increase in his head 
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circumference. On physical exam at the age of 10 months, 
the child had poor weight gain (weight: 6.6 kg), large (48 
cm) head circumference (above 95% percentile), visual 
problem (poor eye contact and impaired fixing and 
following), and a sluggish response to sound along with 
poor feeding. Based on his mother’s statements the child 
had been floppy at the onset of the disease, but at the age 
of 10 months, he became spastic with bilateral extensor 
plantar response and inability to sit. 
The patient was investigated for possible 
neurodegenerative disease and metabolic work-ups 
such as serum ammonia, lactate, pyruvate, blood 
gas, tandem mass metabolic screening (MS/MS), 
urine organic acid profile and plasma amino acids 
profile through HPLC method were requested. All 
the findings were normal except for an increased 
N-Acetyl-L-Aspartic Acid in urine. However, an 
audio metric brainstem response (ABR) and visual 
evoked potential (VEP) tests have shown abnormal 
findings. Magnetic resonance imaging (MRI) of the 
brain revealed diffuse symmetrical white matter of 
centrum semiovale and involvement of subcortical 
U fibers, along with some degree of hyper intensity 
in the thalamus, basal ganglia, periventricular white 
matter, brainstem and cerebellum. Because of the 
suspicion of Canavan disease on physical examination, 
further laboratory investigation, brain imaging and 
the Aspartoacylase enzyme activity test on the skin 
culture fibroblast were found in favor of the Canavan 
disease. 
ASPA-specific genomic DNA fragments were amplified 
by PCR method using specific sets of primers (Table 
1). DNA sample from the patient was investigated by 
sequencing method. A homozygous missense mutation 
as C.202G>A in exon 1 was found (Figure1). This 
finding has not been reported in literatures. The parent’s 
DNA investigation was not done due to refusal of the 
parents.
Discussion
Canavan disease (CD) is a rare vacuolating 
leukodystrophy that is caused by aspartoacylase 
deficiency (8). The substrate of this enzyme is NAA, 
which is exclusively synthesized in the brain. NAA is 
hydrolyzed by aspartoacylase to acetate that is necessary 
for myelin synthesis and aspartate (6, 9). Deficiency of 
aspartoacylase leads to the accumulation of NAA in the 
brain and pathologically results in spongy degeneration 
of the white matter (2, 9). Clinically, two types of CD 
have been described. The most common type of CD 
is the neonatal/infantile form that is more severe in 
clinical presentation compared to the juvenile type 
of the disease (5, 7). Clinical symptoms of neonatal/
infantile CD usually start between the age of 2 - 6 
months and appears with lethargy, poor feeding, axial 
hypotonia, lack of neck holding in pull to sit maneuver, 
progressive hyperreflexia, spasticity along with 
macrocephaly and developmental regression. Cortical 
blindness and optic atrophy accompanies seizure in 
later stages (7). The clinical course of our patient was 
consistent with the infantile type of CD.
Extraction of c-DNA and gene for human ASPA helps to 
describe the molecular basis of the CD. The only known 
gene for Canavan disease is ASPA gene that is localized 
on the short arm of chromosome 17(17p13-ter region) 
(5). Six exons and five introns are included in this gene 
(4). Investigation of mutations in patients with CD has 
disclosed missense, nonsense and splice-site mutations, 
deletions and or insertions (4). Canavan disease is seen 
commonly in Ashkenazi Jewish population but with 
less prevalence among other ethnicity (2, 5, 7). Two 
predominant mutations E285A and Y231X account 
for 98% of chromosomal mutations among Jewish 
population. A305E is the most prevalent mutation among 
Western Europe English, Dutch and German patients. 
The A305E missense mutation is responsible for 48% 
(24/50) of mutations in western European ancestry 
(10). Y231X (p.Tyr231X) and A305E (p.Ala305Glu) 
mutations result in complete loss of ASPA activity 
function. However, E285A (p.Glu285Ala) mutation has 
about 3% of wild type enzyme activity (5, 10). 
Various genetic mutations among non-Jewish patients 
have been reported. Table 2 presents some of these 
mutations in addition to the type of mutation identified 
in this study (7, 11, 12).
Homozygous mutation as in the exon 1 of ASPA gene 
in the present case is a novel mutation that was not 
reported in literatures. The severity of brain involvement 
in current study does not seem to be different from the 
other mutations while it was relatively severe. Cultured 
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skin fibroblasts are required to confirm ASPA deficiency 
and to determine carrier state or disease in high-risk 
individuals. The cultured skin fibroblasts of the patient 
in our study also confirmed that the patient had ASPA 
deficiency. Had the mutation that caused the CD been 
specified in the family, it would make prenatal diagnosis 
possible and to recommend parents with such disorder to 
plan for the next pregnancy.
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Table1. List of primers that have been used for genetic 














Fig 1. Homozygous mutation as C.202G>A
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